NCT06248411 2026-03-18
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
Clinical Trials
23 trialsNCT06234397 2026-03-11
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT05957081 2025-12-30
MarkV-01
PharmAbcine
Phase 1 Recruiting
NCT06724016 2025-12-17
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT07260305 2025-12-03
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
Phase 1 Recruiting
NCT06752681 2025-10-10
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1 Recruiting
NCT06548217 2025-07-03
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT05785754 2025-06-26
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
Phase 1 Recruiting
NCT03155061 2025-06-05
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT05598151 2025-04-30
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT06074497 2025-02-07
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
Phase 1 Active not recruiting
NCT02261532 2024-11-14
A Phase I Study of TAS-102 in Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT06196762 2024-10-10
Phase I of XKH002 Injection in Patients
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase 1 Recruiting
NCT05496595 2024-03-06
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
Phase 1 Terminated
NCT03730337 2023-10-04
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT05848466 2023-05-08
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Unknown
NCT05407909 2022-08-09
To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT03248843 2022-02-08
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed
NCT04427774 2021-07-20
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT02004548 2015-12-29
Phase I Clinical Study of Metatinib Tromethamine Tablet
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT00276913 2014-02-03
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT01014429 2012-09-07
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
Phase 1 Completed
NCT01506934 2012-08-28
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Abbott
Phase 1 Terminated